We’re one of the first firms to deliver coverage of foreign growth companies tailored specifically to U.S. investors.
With domestic investors increasingly looking beyond U.S. borders for diversification, income flow, and currency protection, the need for reliable, thorough investment research has never been greater. Chardan’s equity research group answers this call with timely, detailed coverage of international growth companies—tailored specifically to U.S. investors.
Chardan’s research analysts apply their extensive international equity experience to the identification of promising companies in the $50 million—$1 billion market capitalization range.
We uncover quality opportunities—well-run companies with strong potential—to help managers increase their international reach and exposure.
Our timely updates on regional, industry, and company developments keep clients apprised of market conditions that could affect their investments.
Chardan’s coverage universe includes growth equities listed on exchanges in NYSE, Nasdaq and AMEX.
Our target sectors include Biotechnology, healthcare, energy, defense. Industrials, software and semiconductors.
In the coming months, we plan to initiate coverage of several companies in the Energy and Biotechnology sector, and look to expand the breadth of our coverage from approximately 15 growth companies to 50.
In combination with our vast network of global relationships, our physical presence in China and Australia provides Chardan’s research group with unique access to local and regional market character and color.
Our analysts maintain active contact with both our institutional client base and the management of the companies we cover—providing our investors with a significant edge.
We issue research reports and press releases early in the morning – using global time zones to our advantage—to give U.S. managers ample time to digest information and place buy/sell orders before the foreign exchanges open.